Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Should You Buy Zomedica Stock Right Now?

By Cory Renauer - Jan 13, 2021 at 6:51AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A booming market for pet care could push this soaring stock even higher.

Investors excited about a new diagnostic platform have been pushing shares of Zomedica ( ZOM -13.16% ) through the roof recently. The stock has already doubled in 2021, and a successful launch this spring could push it up even higher. Zomedica stock also got a recent boost when Tiger King star Carole Baskin mentioned the company in a Cameo video she was paid to record.

People sheltering in place during the COVID-19 pandemic adopted a lot of pets, accelerating a long-running trend toward increased spending on pet care services. Can Zomedica and its patented point-of-care tests for adrenal and thyroid diseases deliver big gains for investors?

Life science professionals at work.

Image source: Getty Images.

Let's weigh the big reasons to buy Zomedica stock now against reasons to remain cautious.

Reasons to buy Zomedica

People staying home to avoid spreading the coronavirus adopted a lot of pets in 2020, accelerating demand for veterinary services that was already trending upward. The American Pet Products Association expects total U.S. spending on pets to reach a record $99 billion in 2021.

The sliver of the pet care market associated with diagnostic services is expected to reach $2.8 billion annually by 2024, and Zomedica has a plan to become a major player in this arena. This spring, the company intends to launch Truforma, a tool to help veterinarians detect adrenal and thyroid issues in dogs and cats.

Veterinarians that suspect a hormone condition currently send blood samples out to larger reference laboratories. Zomedica's self-installed Truforma platform is a little bigger than a toaster so veterinarians can provide results on their own without keeping clients waiting.

At recent prices, Zomedica is still a small-cap stock with a market value of about $643 million at recent prices. Shares of diagnostics stocks generally trade at mid-single-digit multiples of annual sales and Zomedica stock could soar if the company quickly gains a significant share of a growing market. Global spending on diagnostic services for companion animals is expected to rise by around 10% annually and reach $2.8 billion by 2024.

Reasons to remain cautious

The Truforma platform relies on Bulk Acoustic Wave (BAW) technology Zomedica licensed from Qorvo ( QRVO 0.49% ) for $5.4 million upfront in 2018. Qorvo's a global semiconductor supplier with more than $4 billion in annual revenue. Qorvo's technology allows a wide variety of electronic devices to communicate, but measuring thyroid hormone concentrations in blood samples is far outside Qorvo's area of expertise.

New smartphones use BAW filters from Qorvo to isolate specific frequency bands, and coating them the filters with biologic reagents appears to allow them to measure biomarkers such as concentrations of circulating hormones. While the technique seemed successful during small verification tests, Zomedica still hasn't completed larger validation studies with any of its assays yet. 

In the spring of 2020, Zomedica completed thyroid hormone verification studies using around 100 samples and the results correlate strongly with standard tests. Zomedica has since blamed the COVID-19 pandemic for slowing down validation studies to be run on much larger batches.

Just a minute

Zomedica intends to launch Truforma at the end of March, but that won't happen if the company can't produce successful validation data. That means there's still a chance the company won't have any source of revenue for the foreseeable future.

One year is a very long time to prepare for a validation study and this slow pace of development at a time the company should be pushing forward at full speed is more than a little disturbing.

Investors eager to invest in Zomedica should at least wait until after Truforma tests have been successfully validated, and until after the company show signs of a successful commercial launch.

The toaster-sized Truforma platform offers on-site convenience, but we don't know if veterinarians will be willing to invest in one. The diagnostics industry is intensely competitive and there's a real chance that Zomedica won't be able to find a pricing structure that lures veterinarians away from the testing procedures they're already used to.

This is an interesting stock to keep your eyes on, but it probably isn't worth the risk right now.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.33 (-13.16%) $0.05
Qorvo, Inc. Stock Quote
Qorvo, Inc.
$149.91 (0.49%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.